Medeze Group Public Company Limited

2024

Industry Champions of the Year

Medeze Group Public Company Limited

Industry Champions of the Year

2024

ABOUT Medeze Group Public Company Limited

Pushing the Boundaries of Longevity Science

“Thailand’s Medeze Group Public Company Limited sets an outstanding benchmark in regenerative healthcare.”

The ACES Award for Industry Champions of the Year highlights companies that drive progress and innovation in their sectors, As one of this year’s recipients. Thailand’s Medeze Group Public Company Limited is celebrated as the nation’s largest and most established mesenchymal stem cell bank, taking a leading role in Southeast Asia’s stem cell banking and regenerative medicine fields. Founded in 2010 as Bangkok Stem Cell, Medeze has grown from a focused stem cell storage provider into a pioneering force, recognized for its advanced cell banking technologies, exacting quality standards, and strategic global reach.

Medeze’s transformation into an industry leader reflects its agility in adapting to evolving healthcare needs. Initially focused on stem cell banking for umbilical cord blood, Medeze expanded to offer cutting-edge therapies for both preventive and regenerative health. Its journey has been marked by continuous investment in state-of-the-art technology and strict quality protocols, forming the foundation for its growth.

Today, Medeze operates the largest world-class stem cell laboratories in Southeast Asia, equipped with Class 10 Cleanroom certification from the National Environmental Balancing Bureau, USA (NEBB), and adheres to American Association of Blood Banks (AABB) standards. This commitment to operational excellence supports Medeze’s scientific advancements, ensuring that the company meets the highest standards of safety and efficacy.

As the company’s services evolved alongside industry demand, Medeze introduced Thailand’s first mesenchymal stem cell (MSC) storage for umbilical cord tissue and the world’s first adipose tissue storage service. These versatile stem cells are used in groundbreaking applications for organ repair and treating major conditions, including heart disease, diabetes, and neurodegenerative disorders.

In addition, Medeze’s MSC storage services meet the rising demand for anti-aging and health optimization therapies, positioning the company within the expanding “science of longevity” field. This foresight drives Medeze’s commitment to longevity-focused healthcare through ongoing research and development collaborations with premier universities and research institutions across Southeast Asia.

A significant milestone in Medeze’s progress is its development of an NK cell immunotherapy program, capitalizing on global immune health awareness. NK (Natural Killer) cells play a crucial role in the immune system’s defense against pathogens and cancer cells. The lab-enhanced NK cells boost immune response, with the therapy patented in collaboration with Japanese scientists Dr. Junichi Masuyama and Dr. Sanehiko Fujita. This innovation distinguishes Medeze’s approach to immunotherapy, addressing the growing demand linked to chronic illnesses and cancer rates worldwide.

As a pioneer in regenerative medicine, Medeze’s impact is extended through its geographical presence and strategic partnerships. Headquartered in Thailand, the company maintains an extensive network spanning nine countries, including Singapore, Vietnam, Taiwan, Cambodia, Myanmar, and Indonesia. With partnerships across 206 hospitals and clinics in Thailand alone, including Bangkok Hospital and Bumrungrad Hospital, Medeze provides access to its advanced medical solutions for thousands of clients across Asia-Pacific, with representation in Europe, Australia, and New Zealand. This expansive distribution network strengthens Medeze’s accessibility and positions it as a trusted partner for individuals seeking advanced medical solutions for preventive and restorative health.

The ACES Award not only celebrates Medeze’s commitment to a sustainable business model based on innovation, integrity, and international standards but also recognizes its corporate responsibility initiatives. The Bangkok Stem Cell Foundation, established in 2015, promotes education, research, and treatment in Thailand, reflecting Medeze’s dedication to advancing public health through accessible education on the potential of stem cell therapies. This philanthropic approach underscores Medeze’s purpose-driven ambition beyond financial success.

Financially, Medeze’s strong growth underscores its industry leadership. With a registered capital of THB 400 million and a debt-free structure, the company has consistently grown its revenue and profitability, reaching a 35.46% net profit margin by Q3 2023. Stem cell banking services account for over 80% of Medeze’s revenue, with NK cell therapy contributing significantly to the remaining share. This financial strength supports Medeze’s continued investment in R&D and capacity expansion in regenerative medicine and immunotherapy.

As the global stem cell and regenerative medicine market is projected to reach USD 26.4 billion by 2026, Medeze is strategically positioned to lead this transformative sector. The company’s future-focused mission aims to deliver longevity and health optimization solutions worldwide, setting a new industry standard. With numerous accolades, including multiple Frost & Sullivan awards, Medeze’s excellence in operational quality, market foresight, and commitment to customer value is reaffirmed.

Winning the Industry Champions of the Year award underscores Medeze Group’s role as a frontrunner in regenerative healthcare. With robust financial health, scientific innovation, and a dedication to quality, Medeze represents the gold standard for success, embodying the progressive spirit that the ACES Awards aim to celebrate.